

## Dolly Kervitsky RCP, CCRC, CNP

Dolly Kervitsky is the Managing Principal of PF Strategies a consulting company that is dedicated to serving the rare disease community. Dolly also serves as the Vice President of Outreach for FluidIQ, a technology company dedicated to the research and development of fluidic based products to be utilized in emergency preparedness protocols.

Dolly began her career as a Teaching Assistant and Supervisory Tutor leading a team in underserved districts in Albuquerque, New Mexico. Her desire to work in healthcare ultimately led to her enrollment in the Respiratory Therapy Program at Central New Mexico Community College. Following graduation, she worked in pediatric, adult and specialty intensive care units at the Bernalillo County Medical Center. Originally the only medical center dedicated to serving the area's Native American communities, it was later renamed the University of New Mexico Hospital. In 1981, Dolly moved to Denver Colorado where she served as the acting-director of Respiratory therapy for National Jewish Hospital.

It was through her work on a research team investigating idiopathic pulmonary fibrosis that she became interested in research as a career. Being recruited to join this team of world-renowned researchers, positioned her to assist in the development and implementation of the Interstitial Lung Disease (ILD) Program at National Jewish Health. This program became the model for other ILD Programs nationwide. Dolly worked closely with physician researchers from around the world. Some physicians wanted to start their own programs, and some simply wanted to collaborate on data mining utilizing the program's vast patient database and biospecimen repository Dolly helped construct. In 2000 she earned her certification in clinical research coordination. She has served on medical advisory committees for large and small pharmaceutical companies, as well as worked closely with the National Institutes of Health on developing and implementing clinical trials for rare diseases. As an avid advocate for rare diseases, she collaborated with Advocacy Organizations as a medical educator developing and hosting patient and healthcare provider symposiums and workshops, all while actively advocating for patient rights on Capitol Hill.

Dolly managed the ILD Clinical and Translational Research Program until 2011 when she joined the Pulmonary Fibrosis Foundation as the Vice President of Patient Relations and Medical Affairs. During her time at the foundation, she developed and implemented many of its signature programs and educational literature while traveling worldwide to advocate and educate patients, caregivers, and healthcare providers. Through global networking, she assisted advocates and healthcare providers to form Respiratory Health Foundations and implement programming in several European countries. In 2015 she earned a certification in Non-Profit Management from Purchase College, University of New York.

In 2015 she joined the Medical Affairs Company as a Medical Science Liaison (MSL) supporting both small clinical-stage and large global pharmaceutical companies. Her responsibilities included communicating clinical and scientific data while providing technical/practical education to various stakeholders within the pulmonary, hematology, autoimmune, and infectious disease communities. She developed, coordinated, and assisted with the implementation of corporate, scientific, and clinical strategies to thought leaders within academic, clinical, and health care

## Dolly Kervitsky RCP, CCRC, CNP

organizations. She was responsible for representing the Sponsor within clinical research organizations (CRO's) to educate thought leaders on pharmaceutical agents and devices being utilized in clinical trials while acting as the medical resource for CRO staff and clinical study site staff.

In 2018, Dolly began to focus her efforts on volunteer and consulting projects, assisting patient advocates and small pharmaceutical companies. In 2020, during the COVID-19 pandemic, she became part of a volunteer team of engineers, physicians, respiratory therapists, and patient advocates that were researching the development of a novel ventilator. This team of volunteers formed a public benefit corporation, FluidIQ, to further the development of fluidic devices for use in emergency preparedness protocols in austere environments. She continues to serve as the Managing Principal of PF Strategies and also as the VP of Outreach for FluidIQ.